Early ADHD Medication May Lower Risk of Psychotic Disorders Later in Life

A large-scale study has found that treating ADHD with stimulant medications in childhood may cut the risk of severe psychotic disorders in later life. The research, published in JAMA Psychiatry, challenges long-standing concerns about the long-term safety of these drugs. Experts say the findings could reassure parents and doctors who have worried about potential risks like schizophrenia. The study tracked thousands of individuals and discovered that children who received stimulant treatment for ADHD—particularly before age 13—were less likely to develop serious psychotic conditions as adults. This protective effect did not extend to those who began treatment in adolescence or adulthood. Researchers used advanced statistical techniques to rule out regional differences in prescribing habits, ensuring the results were robust.

Dr. Colm Healy, the study's lead author, highlighted the need for age-specific research as ADHD diagnoses in adults continue to climb. The team found no evidence that methylphenidate, a common ADHD medication, increased the risk of psychosis later in life. Instead, early intervention appeared to offer long-term mental health benefits. The findings align with recent shifts in public perception and medical guidelines. Over the past decade, studies—including a 2023 *Lancet Psychiatry* report—have confirmed that methylphenidate does not raise long-term risks of psychiatric or neurological side effects in children. European consensus already recommends it as a first-line therapy, and the new research reinforces its safety profile. Professor Ian Kelleher, who led the study, stressed that early diagnosis and evidence-based treatment remain critical for managing ADHD effectively.

The research suggests that childhood stimulant treatment for ADHD may provide lasting protection against severe mental illness. Clinicians and families now have stronger evidence that early, well-managed medication does not harm long-term mental health. Instead, it may reduce the risk of conditions like schizophrenia in adulthood.